Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
01 nov. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
13 oct. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference
09 sept. 2021 11h46 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
07 sept. 2021 07h30 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
21 juin 2021 09h15 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
19 juin 2021 18h30 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 19, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
17 juin 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all...
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
27 mai 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an...
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
17 mai 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received...
Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
11 mai 2021 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional...